Literature DB >> 21852382

Haploinsufficiency in the prometastasis Kiss1 receptor Gpr54 delays breast tumor initiation, progression, and lung metastasis.

Sung-Gook Cho1, Ying Wang, Melissa Rodriguez, Kunrong Tan, Wenzheng Zhang, Jian Luo, Dali Li, Mingyao Liu.   

Abstract

Activation of KISS1 receptor (KISS1R or GPR54) by its ligands (Kisspeptins) regulates a diverse function both in normal physiology and pathophysiology. In cancer, KISS1R has been implicated in tumor angiogenesis and metastasis, but a broader evaluation of KISS1R in tumorigenesis and tumor progression is yet to be conducted. In this study, we used mouse models of Kiss1r gene knockout and mouse mammary tumor virus-polyoma virus middle T antigen (MMTV-PyMT)-induced breast cancer to conduct such an evaluation. Kiss1r heterozygosity in MMTV-PyMT mice was sufficient to attenuate breast cancer initiation, growth, latency, multiplicity, and lung metastasis. To confirm these effects and assess possible contributions of endogenous ligands, we isolated primary tumor cells from PyMT/Kiss1r(+/+) and PyMT/Kiss1r(+/-) mice and compared their phenotypes by in vitro and in vivo assays. Kiss1r loss attenuated in vitro tumorigenic properties as well as tumor growth in vivo in immunocompromised NOD.SCID/NCr mice. Kiss1r activation in these cells, resulting from the addition of its ligand Kisspeptin-10, resulted in RhoA activation and RhoA-dependent gene expression through the Gαq-p63RhoGEF signaling pathway. Anchorage-independent growth was tightly linked to dose-dependent regulation of RhoA by Kiss1r. In support of these results, siRNA-mediated knockdown of KISS1R or inactivation of RhoA in human MCF10A breast epithelial cells overexpressing H-RasV12 was sufficient to reduce Ras-induced anchorage-independent growth. In summary, we concluded that Kiss1r attenuation was sufficient to delay breast tumor initiation, progression, and metastasis through inhibitory effects on the downstream Gαq-p63RhoGEF-RhoA signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21852382      PMCID: PMC4949591          DOI: 10.1158/0008-5472.CAN-11-0329

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

Review 1.  Understanding complex signaling networks through models and metaphors.

Authors:  Upinder S Bhalla
Journal:  Prog Biophys Mol Biol       Date:  2003-01       Impact factor: 3.667

2.  Structure of Galphaq-p63RhoGEF-RhoA complex reveals a pathway for the activation of RhoA by GPCRs.

Authors:  Susanne Lutz; Aruna Shankaranarayanan; Cassandra Coco; Marc Ridilla; Mark R Nance; Christiane Vettel; Doris Baltus; Chris R Evelyn; Richard R Neubig; Thomas Wieland; John J G Tesmer
Journal:  Science       Date:  2007-12-21       Impact factor: 47.728

3.  Reduced metastasis-suppressor gene mRNA-expression in breast cancer brain metastases.

Authors:  Andreas M Stark; Kerrin Tongers; Nicolai Maass; H Maximilian Mehdorn; Janka Held-Feindt
Journal:  J Cancer Res Clin Oncol       Date:  2004-12-08       Impact factor: 4.553

4.  Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis.

Authors:  Szu-Wei Lee; Chien-Feng Li; Chia-Hsin Chan; Jing Wang; Wei-Lei Yang; Ching-Yuan Wu; Juan Wu; Keiichi I Nakayama; Hong-Yo Kang; Hsuan-Ying Huang; Mien-Chie Hung; Pier Paolo Pandolfi; Hui-Kuan Lin
Journal:  Nat Cell Biol       Date:  2010-04-11       Impact factor: 28.824

Review 5.  The KISS1 metastasis suppressor: mechanistic insights and clinical utility.

Authors:  Kevin T Nash; Danny R Welch
Journal:  Front Biosci       Date:  2006-01-01

6.  MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data.

Authors:  K Quandt; K Frech; H Karas; E Wingender; T Werner
Journal:  Nucleic Acids Res       Date:  1995-12-11       Impact factor: 16.971

7.  Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling.

Authors:  Yuliya Pylayeva; Kelly M Gillen; William Gerald; Hilary E Beggs; Louis F Reichardt; Filippo G Giancotti
Journal:  J Clin Invest       Date:  2009-01-19       Impact factor: 14.808

8.  The GPR54 gene as a regulator of puberty.

Authors:  Stephanie B Seminara; Sophie Messager; Emmanouella E Chatzidaki; Rosemary R Thresher; James S Acierno; Jenna K Shagoury; Yousef Bo-Abbas; Wendy Kuohung; Kristine M Schwinof; Alan G Hendrick; Dirk Zahn; John Dixon; Ursula B Kaiser; Susan A Slaugenhaupt; James F Gusella; Stephen O'Rahilly; Mark B L Carlton; William F Crowley; Samuel A J R Aparicio; William H Colledge
Journal:  N Engl J Med       Date:  2003-10-23       Impact factor: 91.245

9.  Metastin inhibits migration and invasion of renal cell carcinoma with overexpression of metastin receptor.

Authors:  Sunao Shoji; Xian Yan Tang; Shinobu Umemura; Johbu Itoh; Susumu Takekoshi; Masanori Shima; Yukio Usui; Yoshihiro Nagata; Toyoaki Uchida; Robert Yoshiyuki Osamura; Toshiro Terachi
Journal:  Eur Urol       Date:  2008-03-11       Impact factor: 20.096

10.  Large isoform of MRJ (DNAJB6) reduces malignant activity of breast cancer.

Authors:  Aparna Mitra; Rebecca A Fillmore; Brandon J Metge; Mathur Rajesh; Yaguang Xi; Judy King; Jingfang Ju; Lewis Pannell; Lalita A Shevde; Rajeev S Samant
Journal:  Breast Cancer Res       Date:  2008-03-07       Impact factor: 6.466

View more
  19 in total

1.  KISS1 methylation and expression as predictors of disease progression in colorectal cancer patients.

Authors:  Shao-Qin Chen; Zhi-Hua Chen; Su-Yong Lin; Qi-Bao Dai; Leng-Xi Fu; Rui-Qing Chen
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

2.  LGR4 modulates breast cancer initiation, metastasis, and cancer stem cells.

Authors:  Zhiying Yue; Zengjin Yuan; Li Zeng; Ying Wang; Li Lai; Jing Li; Peng Sun; Xiwen Xue; Junyi Qi; Zhengfeng Yang; Yansen Zheng; Yuanzhang Fang; Dali Li; Stefan Siwko; Yi Li; Jian Luo; Mingyao Liu
Journal:  FASEB J       Date:  2017-12-21       Impact factor: 5.191

3.  Lgr4 regulates mammary gland development and stem cell activity through the pluripotency transcription factor Sox2.

Authors:  Ying Wang; Jie Dong; Dali Li; Li Lai; Stefan Siwko; Yi Li; Mingyao Liu
Journal:  Stem Cells       Date:  2013-09       Impact factor: 6.277

Review 4.  KISS1 in metastatic cancer research and treatment: potential and paradoxes.

Authors:  Thuc Ly; Sitaram Harihar; Danny R Welch
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

Review 5.  Role of the tumor microenvironment in regulating the anti-metastatic effect of KISS1.

Authors:  Sitaram Harihar; Srijit Ray; Samyukta Narayanan; Anirudh Santhoshkumar; Thuc Ly; Danny R Welch
Journal:  Clin Exp Metastasis       Date:  2020-02-22       Impact factor: 5.150

6.  The effects of kisspeptin-10 on migration and proliferation of endothelial cell.

Authors:  Fatemeh Golzar; Shaghayegh Haghjooy Javanmard
Journal:  Adv Biomed Res       Date:  2015-02-11

7.  The effect of Kisspeptin-10 on mesenchymal stem cells migration in vitro and in vivo.

Authors:  Fatemeh Golzar; Shaghayegh Haghjooy Javanmard; Vahid Bahrambeigi; Laleh Rafiee
Journal:  Adv Biomed Res       Date:  2015-01-30

Review 8.  Kisspeptin/KISS1R System in Breast Cancer.

Authors:  Donna Cvetković; Andy V Babwah; Moshmi Bhattacharya
Journal:  J Cancer       Date:  2013-09-26       Impact factor: 4.207

9.  The retinoblastoma protein regulates hypoxia-inducible genetic programs, tumor cell invasiveness and neuroendocrine differentiation in prostate cancer cells.

Authors:  Mark P Labrecque; Mandeep K Takhar; Rebecca Nason; Stephanie Santacruz; Kevin J Tam; Shabnam Massah; Anne Haegert; Robert H Bell; Manuel Altamirano-Dimas; Colin C Collins; Frank J S Lee; Gratien G Prefontaine; Michael E Cox; Timothy V Beischlag
Journal:  Oncotarget       Date:  2016-04-26

10.  Herbal Prescription, DSGOST, Prevents Cold-Induced RhoA Activation and Endothelin-1 Production in Endothelial Cells.

Authors:  Sung-Gook Cho; Ho Yeon Go; Jeong-Su Park; Ki-Yong Jung; Seung-Ho Sun; You-Kyung Choi; Yun-Kyung Song; Jong-Hyeong Park; Chan-Yong Jun; Seong Gyu Ko
Journal:  Evid Based Complement Alternat Med       Date:  2014-04-15       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.